UPB
Upstream Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$347.20M
P/E Ratio
—
EPS
$-2.90
Beta
—
52W High
$33.68
52W Low
$5.85
50-Day MA
$8.86
200-Day MA
$17.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.32M |
| Gross Profit (TTM) | $3.32M |
| EBITDA | $-171.77M |
| Operating Margin | -4218.00% |
| Return on Equity | -41.80% |
| Return on Assets | -27.80% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $6.26 |
| Price-to-Book | 1.14 |
| Price-to-Sales (TTM) | 104.52 |
| EV/Revenue | 16.18 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 82.70% |
| Shares Outstanding | $54.42M |
| Float | $34.97M |
| % Insiders | 14.88% |
| % Institutions | 90.10% |
Historical Volatility
HV 10-Day
82.92%
HV 20-Day
72.32%
HV 30-Day
64.98%
HV 60-Day
66.59%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($41.62 target)
2
Strong Buy5
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026